Federated Hermes’s Aldeyra Therapeutics ALDX Stock Holding History

Federated Hermes’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,962	Closed	-$5.01K	–	2040
2026 Q1	$5.01K	Buy	+2,962	New	+$13K	﹤0.01%	1889
2025 Q2	–	Sell	-551,091	Closed	-$3.17M	–	2059
2025 Q1	$3.17M	Buy	551,091 +714	+0.1%	+$4.22K	0.01%	824
2024 Q4	$2.75M	Buy	550,377 +813	+0.1%	+$4.17K	0.01%	859
2024 Q3	$2.96M	Buy	549,564 +18,343	+3%	+$87.3K	0.01%	844
2024 Q2	$1.76M	Buy	+531,221	New	+$2.08M	﹤0.01%	952
2024 Q1	–	Sell	-243	Closed	-$853	–	2026
2023 Q4	$853	Sell	243 -20,820	-99%	-$64.2K	﹤0.01%	1984
2023 Q3	$141K	Hold	21,063	–	–	﹤0.01%	1568
2023 Q2	$177K	Buy	+21,063	New	+$208K	﹤0.01%	1565
2021 Q2	–	Sell	-86	Closed	-$1K	–	2196
2021 Q1	$1K	Buy	+86	New	+$990	﹤0.01%	2148
2020 Q4	–	Sell	-144	Closed	-$1K	–	2231
2020 Q3	$1K	Buy	+144	New	+$930	﹤0.01%	2132

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Federated Hermes's ALDX Position: Q2 2026 in Review

Federated Hermes sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 2,962 shares — an estimated $5.01K sold.

Federated Hermes first reported a position in ALDX in Q3 2020 and held it in 10 quarters. The position peaked at $3.17M in Q1 2025. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Federated Hermes reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
Federated Hermes sold 2,962 Aldeyra Therapeutics shares in Q2 2026, an estimated $5.01K.
Federated Hermes first reported a position in Aldeyra Therapeutics in Q3 2020 and held it in 10 quarters.
Federated Hermes's Aldeyra Therapeutics position peaked at $3.17M in Q1 2025.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.